Education
About Us
Working with TipRanks
Follow Us
Lisata Therapeutics (LSTA)
NASDAQ:LSTA
Gemcitabine, Nab-paclitaxel, Certepetide
Pancreas Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Pancreas Cancer, Pancreatic Carcinoma, Unresectable Pancreatic Cancer, Pdac, Pdac - Pancreatic Ductal Adenocarcinoma
Phase I/II
Withdrawn
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
Sep 09, 2024
―
Gemcitabine, Durvalumab, Cisplatin, Certepetide, Folfox Regimen
Bile Duct Cancer, Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Gall Bladder Cancer, Gall Bladder Carcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Extrahepatic Cholangiocarcinoma
Phase II
Active Not Recruiting
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
Jan 26, 2023
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Lisata Therapeutics (LSTA) have in its pipeline
LSTA is currently developing the following drugs: Gemcitabine, Nab-paclitaxel, Certepetide, Gemcitabine, Durvalumab, Cisplatin, Certepetide, Folfox Regimen. These drug candidates are in various stages of clinical development as the company works toward FDA approval.